Supporting Information

Obesity Differs from Diabetes Mellitus in Antibody and T Cell Responses Post COVID-19 Recovery

Mohammad Ali(1,2,3,4), Stephanie Longet(5), Isabel Neale(1,2,3), Patpong Rongkard(1,2,3), Forhad Uddin Hassan Chowdhury(6), Jennifer Hill(1,2,3), Anthony Brown(1), Stephen
Laidlaw(5), Tom Tipton(5), Ashraful Hoque(7), Nazia Hassan(8), Carl-Philipp Hackstein(1,9), Sandra Adele(1,2,3), Hossain Delowar Akther (1,9), Priyanka Abraham(1,2,3), Shrebash Paul(8), Md Matiur Rahman(10), Md Masum Alam(10), Shamima Parvin(11), Forhadul Hoque Mollah(10), Md Mozammel Hoque(10), Shona C Moore(12), Subrata K Biswas(10, 14), Lance Turtle(12), Thushan I de Silva(13), Ane Ogbe(1), John Frater(1), Eleanor
Barnes(1,2,15), Adriana Tomic (16, 17, 18), Miles W Carroll(5), Paul Klenerman(1,2,9,15), Barbara Kronsteiner(1,2,3), Fazle Rabbi Chowdhury(3,8), Susanna J Dunachie(1,2,3,15)

[1] Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK

[2] Centre for Global Health Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK

[3] Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand

[4] Directorate General of Health Services, Dhaka, Bangladesh

[5] Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK

[6] Department of Internal Medicine, Dhaka Medical College, Dhaka, Bangladesh

[7] Department of Transfusion Medicine, Sheikh Hasina National Burn & Plastics Surgery Institute, Dhaka, Bangladesh

[8] Department of Internal Medicine, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

[9] Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK

[10] Department of Biochemistry and Molecular Biology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

[11] Department of Biochemistry and Molecular Biology, Mugda Medical College, Dhaka, Bangladesh[12] Tropical and Infectious Disease Unit, Liverpool University Hospitals NHS Foundation Trust,Member of Liverpool Health Partners, Liverpool, UK

[13] Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK

[14] Department of Molecular and Cell Biology, University of Connecticut, Storrs, Connecticut, USA[15] NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

[16] National Emerging Infectious Diseases Laboratories, Boston University, USA

[17] Department of Microbiology, Boston University School of Medicine, USA

[18] Department of Biomedical Engineering, Boston University, Boston, MA, USA

Contact Info:

Susanna Dunachie, Peter Medawar Building for Pathogen Research, University of Oxford, OX1 3SY, Oxford, UK. Email: susie.dunachie@ndm.ox.ac.uk



Figure S1: The breadth of T cell responses to SARS-CoV-2 was higher in patients who recovered from severe COVID-19.

Barplots on the left display the number of viral proteins recognised in individuals across groups (coloured by specificity) by (A) ex vivo IFN-γ ELISpot assay, (B) CD4+ T cell proliferation, (C) CD8+ T cell proliferation. Dot plots on the right show the comparison of the number of viral proteins recognised among groups by corresponding assays.

A two-tailed Wilcoxon rank-sum test was used to compare between the groups (without correction for multiple testing), p values are shown on the top of the dot plots The number of individuals (n) evaluated per assay is displayed at the bottom of the corresponding dot plots, while horizontal bars represent the medians.

Α

В



Gating strategy for antigen-specific T cell cytokine secretion (ICS)



Figure S2: Gating strategy for T cell proliferation and intracellular cytokine staining (ICS).

(A) For T cell proliferation assays, lymphocytes were gated using forward and side scatter area (FSC-A and SSC-A) parameters, followed by single cell gating on FSC-height (H) and area (A). Live T cells were then gated (LD-NiR low CD3+) and T cell subsets were identified (CD4+CD8- and CD8+CD4-) using CD4+ APC and CD8+ PE-Cy7. Within the CD4+ and the CD8+ T cell gate proliferating cells were identified by gating on cells with reduced CTV (CellTraceTM Violet) fluorescence intensity.

(B) For ICS assays lymphocytes were gated using forward and side scatter area (FSC-A and SSC-A) parameters, followed by single cell gating on FSC-height (H) and area (A). Live CD3+ T cells were gated based on exclusion of dead cells (LD-NiR) and monocytes (CD14 APC Fire-750) as well as positivity for CD3 PerCP. T cell subsets were identified based on staining for CD4 APC and CD8 BV510 respectively and expression of cytokines (IFN- γ , TNF, IL-2) was then identified in the CD4+CD8- gate as well as the CD8+CD4- gate. Representative gating is shown for the DMSO negative control and the reactive peptide pools.







Α

Antigen-specific T cells: Non-DM vs DM



Figure S3: Overweight/obese status is associated with increased T cell cytokine responses to SARS-CoV-2 after recovery, but the cytokine responses are similar between diabetic and non-diabetic recovered patients.

Comparison of cytokine responses (IFN-γ, IL-2 and TNF) by CD4⁺ and CD8⁺ T cells in response to SARS-CoV2 spike (top panel) and M+N pools (bottom panel) between (A) lean and overweight/obese (Ov/Ob), (B) non-diabetic (Non-DM) and diabetic (DM) recovered COVID-19 patients.

A two-tailed Wilcoxon rank-sum test was used to compare between the groups (without correction for multiple testing), with fold changes in brackets. P values are displayed in case of significant differences. The number of individuals (n) evaluated per assay is displayed at the bottom of the corresponding dot plots. Horizontal bars represent the medians, and the median values are shown in brackets immediately above the number of individuals (n) in each column.

Correlation between IgG and neutralising antibodies

Α

С



Correlation between IgG and memory B cells

Anti-spike B cell vs anti-spike IgG Anti-N B cell vs anti-N IgG Anti-spike antibody SFUs/million PBMCs Anti-N antibody SFUs/million PBMCs R = 0.55 , P < 0.0001 R = 0.57 , P < 0.0001 750[.] 200-500· 100 250[.] \bigcirc \cap \bigcirc 0 0 \square 100 1000 10000 10000 100000 1000000 100000 1000 10 100 Anti-spike IgG (AU/mL) Anti-N IgG (AU/mL)

Correlation between T cell IFN-y and antibodies

nAb titres vs anti-spike IFN-γ nAb titres vs anti-N IFN-y nAb titres vs anti-M IFN-y 500 R = 0.34 , p = 0.043 R = 0.34, p = 0.04R = 0.28, p = 0.097Anti-Spike IFN-y SFUs/million PBMCs 150 Anti-N IFN-Y SFUs/million PBMCs Anti-M IFN-y SFUs/million PBMCs 300 400 100 300 200 200 50 100 100 0 0 ė ġ 00 ġ ŝ 8 ģ ė Virus neutralisation IC50 Virus neutralisation IC50 Virus neutralisation IC50 Anti-spike IgG vs anti-spike IFN-y Anti-RBD IgG vs anti-spike IFN-γ Anti-N IgG vs anti-N IFN-γ 500 500 R = 0.55, P < 0.000 = 0.53 , P < 0.0001 R = 0.3 , p = 0.0082 Anti-spike IFN-y SFUs/million PBMC 150 PBMC Anti-N IFN-V SFUs/million PBMC 400 400 100 SFUs/m 300 300 200 200 50 Spike 100 100 0 0 ŝ ŝ -10 -0000 Anti-spike IgG (AU/mL) Anti-RBD IgG (AU/mL) Anti-N IgG (AU/mL)

7

Figure S4: Correlation between antibody, B cell and T cell responses to SARS-CoV-2.

(A) Correlation of neutralising antibody (nAb) titers with IgG responses to SARS-CoV-2 spike, receptor binding domain (RBD), and nucleoprotein (N) in recovered COVID-19 patients.

(B) Correlation between IgG and memory B cell responses to SARS-CoV-2 spike (left) and N (right) in healthy seronegative and seropositive controls and recovered patients.

(C) Correlation of IFN- γ ELISpot responses with IgG and nAb titers in healthy seropositive controls and recovered patients.

Spearman's correlation coefficient (R) and p-values are shown at the top of each plot.

Principal component analysis

Δ



Figure S5: Principal component analysis with integrated immunological data in recovered COVID-19 patients.

(A) PCA plot representing integrated immunological data, grouped based on the diabetes (left) and obesity (right) status. Percentage indicates the variance explained by the principal component (PC).

(B) Quality of variable representations (colour-coded, cos2) and contributions of variables to principal components 1 and 2 (size of the circle).

(C) Top 10 variables and their contribution to PC 1 and 2.

| Variable | Normal weight (N = 20) | Overweight/obesity (N = 52) | p-value |
|---|---------------------------|--------------------------------|--------------------|
| Age in years, median (IQR [#]) | 55 (43, 61) | 43 (34, 53) | 0.020 ª |
| Sex | | | >0.9 ^b |
| Female, n (%) | 3 (15%) | 8 (15%) | |
| Male, n (%) | 17 (85%) | 44 (85%) | |
| Diabetes status | | | 0.082 ^b |
| Non-diabetic, n (%) | 9 (45%) | 35 (67%) | |
| Diabetic, n (%) | 11 (55%) | 17 (33%) | |
| Disease severity | | | >0.9 ^b |
| Mild/moderate, n (%) | 6 (30%) | 22 (42%) | |
| Severe, n (%) | 14 (70%) | 30 (58%) | |
| Days post symptom onset , median (IQR [#]) | 54 (36, 110) | 59 (38, 100) | >0.9 ª |
| #IQR (Interquartile range) a Wilcoxon rank sum test; ^b Pear | son's Chi-squared to | est | |

Table S1a: Demographic characteristics of recovered participants with or without obesity.

Non-diabetic Diabetic p-value Variable (N = 46) (N = 29) <0.001 ^a **Age in years**, median (IQR[#]) 40 (31, 51) 53 (45, 63) >0.9 ^b Sex Female, n (%) 7 (15%) 4 (14%) 39 (85%) 25 (86%) Male, n (%) 0.21 ^b **Obesity category** Normal weight, n (%) 9 (20%) 11 (38%) Overweight/obesity, n (%) 35 (76%) 17 (59%) Data missing, n (%) 2 (4%) 1 (3%) 0.027 ^b **Disease severity** Mild/moderate, n (%) 24 (52%) 7 (24%) 22 (48%) 22 (76%) Severe, n (%) Days post symptom onset, 69 (33, 120) 52 (40, 70) 0.3 ^a median (IQR[#]) [#]IQR (Interquartile range)

Table S1b: Demographic characteristics of recovered participants with or without diabetes.

^a Wilcoxon rank sum test; ^b Pearson's Chi-squared test

| | Α | nti-spike I | gG | 4 | nti-RBD l | βG | | Anti-N Igo | 3 | Neut | ralising an | tibody | Anti-spike memory B cells | | | Anti-N memory B cells | | |
|------------------------------|-------------|--------------|-------------|----------|-----------|---------|---------|------------|---------|---------|-------------|---------|---------------------------|--------|---------|-----------------------|--------|---------|
| Coefficient | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value |
| Age | 0.2615 | 0.1316 | 0.0512 | 0.2219 | 0.1319 | 0.0974 | 0.1134 | 0.1421 | 0.4278 | 0.2088 | 0.1794 | 0.2518 | 0.2054 | 0.2667 | 0.4523 | 0.1126 | 0.2476 | 0.6553 |
| Sex (male) | -0.2075 | 0.2742 | 0.4519 | -0.1770 | 0.2748 | 0.5219 | -0.1592 | 0.2960 | 0.5925 | -0.1880 | 0.3405 | 0.5843 | 0.2552 | 0.5673 | 0.6589 | -0.0994 | 0.5266 | 0.8526 |
| DM (yes) | 0.1133 | 0.2226 | 0.6126 | 0.1848 | 0.2231 | 0.4105 | 0.0159 | 0.2403 | 0.9474 | -0.2130 | 0.3030 | 0.4864 | -0.3309 | 0.4765 | 0.4973 | 0.0078 | 0.4423 | 0.9862 |
| Obesity (yes) | 0.1981 | 0.2264 | 0.3846 | 0.1861 | 0.2269 | 0.4152 | 0.3610 | 0.2444 | 0.1445 | -0.7077 | 0.2788 | 0.0155 | -0.2757 | 0.5925 | 0.6481 | -0.6133 | 0.5501 | 0.2813 |
| Disease Severity (severe) | 0.7628 | 0.2464 | 0.0029 | 0.7212 | 0.2470 | 0.0048 | 0.8410 | 0.2660 | 0.0024 | 0.6099 | 0.3077 | 0.0549 | 0.1470 | 0.5161 | 0.7794 | -0.0677 | 0.4791 | 0.8895 |
| Days pso | -0.1537 | 0.1050 | 0.1482 | -0.2229 | 0.1053 | 0.0381 | -0.1740 | 0.1134 | 0.1296 | -0.1988 | 0.1424 | 0.1711 | 0.2341 | 0.2735 | 0.4047 | 0.3316 | 0.2539 | 0.2100 |
| Est (estimates), SE (sta | andard erro | or), pso (po | ost symptoi | m onset) | | | | | | | | | | | | | | |

Table S2a. Generalised linear regression models of antibody (IgG, neutralising Ab) and memory B cell responses in SARS-CoV-2 recovered patients

| | S1 IFN-y ELISpot S2 IFN-y ELISpot | | | М | IFN-γ ELIS | pot | N | IFN-γ ELIS | pot | ORF3 | +6 IFN-γ E | LISpot | ORF7+8 IFN-γ ELISpot | | | | | |
|------------------------------|-----------------------------------|--------------|-------------|----------|------------|---------|---------|------------|---------|---------|------------|---------|----------------------|--------|---------|---------|--------|---------|
| Coefficient | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value |
| Age | 0.2439 | 0.1633 | 0.1430 | 0.3061 | 0.1728 | 0.0839 | 0.1504 | 0.1691 | 0.3788 | 0.1408 | 0.1752 | 0.4263 | 0.1169 | 0.1730 | 0.5031 | 0.1425 | 0.1779 | 0.4275 |
| Sex (male) | -0.2320 | 0.3547 | 0.5168 | 0.0767 | 0.3752 | 0.8391 | -0.2778 | 0.3672 | 0.4536 | -0.2894 | 0.3806 | 0.4513 | -0.3771 | 0.3758 | 0.3215 | -0.0962 | 0.3863 | 0.8046 |
| DM (yes) | 0.2647 | 0.3047 | 0.3900 | -0.1007 | 0.3223 | 0.7563 | -0.0012 | 0.3154 | 0.9971 | 0.1480 | 0.3269 | 0.6532 | -0.3354 | 0.3228 | 0.3049 | -0.4161 | 0.3319 | 0.2170 |
| Obesity (yes) | 0.6928 | 0.3229 | 0.0379 | 0.4721 | 0.3416 | 0.1745 | 0.6411 | 0.3343 | 0.0621 | 0.5200 | 0.3465 | 0.1410 | 0.3884 | 0.3421 | 0.2628 | -0.0978 | 0.3517 | 0.7823 |
| Disease Severity (severe) | 0.3741 | 0.3112 | 0.2362 | 0.2880 | 0.3292 | 0.3867 | 0.4061 | 0.3221 | 0.2145 | 0.2215 | 0.3339 | 0.5107 | 0.4818 | 0.3297 | 0.1515 | 0.4011 | 0.3389 | 0.2435 |
| Days pso | -0.1033 | 0.1446 | 0.4791 | 0.0355 | 0.1530 | 0.8179 | 0.1950 | 0.1497 | 0.2001 | 0.2164 | 0.1552 | 0.1706 | -0.1146 | 0.1532 | 0.4589 | 0.0359 | 0.1575 | 0.8207 |
| Est (estimates), SE (sta | andard erro | or), pso (po | ost symptoi | m onset) | | | | | | | | | | | | | | |

Table S2b. Generalised linear regression models of IFN-γ T cell ELISpot responses in SARS-CoV-2 recovered patients

| | S1 CI | 04 prolife | ration | S2 C | D4 prolife | ration | M CI | D4 prolife | ration | N CI | 04 prolifer | ation | ORF3+6 | 6 CD4 prol | iferation | ORF7+8 CD4 proliferation | | | |
|------------------------------|-------------|--------------|-------------|----------|------------|---------|---------|------------|---------|---------|-------------|---------|--------|------------|-----------|--------------------------|--------|---------|--|
| Coefficient | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value | |
| Age | 0.2340 | 0.1598 | 0.1504 | 0.2142 | 0.1637 | 0.1978 | 0.0762 | 0.1660 | 0.6486 | 0.1505 | 0.1671 | 0.3727 | 0.3135 | 0.1580 | 0.0536 | 0.4431 | 0.1437 | 0.0036 | |
| Sex (male) | -0.2905 | 0.3594 | 0.4235 | -0.1127 | 0.3682 | 0.7610 | -0.2992 | 0.3734 | 0.4274 | -0.2926 | 0.3758 | 0.4405 | 0.1262 | 0.3553 | 0.7242 | 0.5546 | 0.3231 | 0.0933 | |
| DM (yes) | 0.5313 | 0.3147 | 0.0986 | 0.5313 | 0.3224 | 0.1067 | 0.5095 | 0.3270 | 0.1266 | 0.3326 | 0.3291 | 0.3178 | 0.3569 | 0.3112 | 0.2577 | 0.5901 | 0.2830 | 0.0430 | |
| Obesity (yes) | 0.0663 | 0.3406 | 0.8465 | 0.1532 | 0.3489 | 0.6627 | 0.0884 | 0.3539 | 0.8039 | 0.1225 | 0.3561 | 0.7325 | 0.0989 | 0.3367 | 0.7703 | 0.2534 | 0.3062 | 0.4124 | |
| Disease Severity (severe) | -0.0093 | 0.3172 | 0.9767 | -0.0542 | 0.3249 | 0.8684 | -0.0908 | 0.3296 | 0.7842 | 0.0633 | 0.3317 | 0.8496 | 0.2303 | 0.3136 | 0.4668 | -0.0186 | 0.2852 | 0.9483 | |
| Days pso | 0.0012 | 0.1534 | 0.9936 | 0.0623 | 0.1571 | 0.6935 | -0.0291 | 0.1593 | 0.8558 | 0.0033 | 0.1603 | 0.9839 | 0.0507 | 0.1516 | 0.7398 | 0.0141 | 0.1379 | 0.9193 | |
| Est (estimates), SE (sta | andard erro | or), pso (po | ost symptoi | m onset) | | | | | | | | | | | | | | | |

Table S2c. Generalised linear regression models of CD4 T cell proliferative responses in SARS-CoV-2 recovered patients

| | S1 CD8 proliferation S2 CD8 proliferation | | | | | ration | M CI | D8 prolife | ration | N CI | 08 prolifer | ation | ORF3+6 | CD8 prol | iferation | ORF7+8 CD8 proliferation | | |
|------------------------------|---|--------------|-------------|----------|--------|---------|---------|------------|---------|---------|-------------|---------|---------|----------|-----------|--------------------------|--------|---------|
| Coefficient | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value |
| Age | 0.2227 | 0.1469 | 0.1368 | 0.2834 | 0.1473 | 0.0611 | 0.1215 | 0.1627 | 0.4593 | 0.1715 | 0.1595 | 0.2881 | 0.2439 | 0.1588 | 0.1320 | 0.4568 | 0.1356 | 0.0016 |
| Sex (male) | -0.3662 | 0.3304 | 0.2738 | -0.4932 | 0.3314 | 0.1440 | -0.3724 | 0.3659 | 0.3145 | -0.1622 | 0.3587 | 0.6534 | -0.2693 | 0.3573 | 0.4551 | 0.1134 | 0.3049 | 0.7118 |
| DM (yes) | 0.4680 | 0.2893 | 0.1131 | 0.3532 | 0.2902 | 0.2301 | 0.3330 | 0.3204 | 0.3044 | 0.2438 | 0.3141 | 0.4419 | 0.0904 | 0.3128 | 0.7740 | 0.3822 | 0.2670 | 0.1595 |
| Obesity (yes) | 0.6695 | 0.3131 | 0.0382 | 0.8002 | 0.3140 | 0.0145 | 0.5399 | 0.3467 | 0.1268 | 0.4656 | 0.3399 | 0.1779 | 0.4066 | 0.3386 | 0.2364 | 0.8032 | 0.2889 | 0.0080 |
| Disease Severity (severe) | 0.4684 | 0.2916 | 0.1155 | 0.2513 | 0.2924 | 0.3950 | 0.1253 | 0.3229 | 0.6999 | 0.4430 | 0.3166 | 0.1689 | 0.3634 | 0.3153 | 0.2554 | 0.3205 | 0.2691 | 0.2402 |
| Days pso | 0.0863 | 0.1410 | 0.5436 | 0.0462 | 0.1414 | 0.7453 | 0.1522 | 0.1561 | 0.3351 | 0.0701 | 0.1531 | 0.6491 | 0.0480 | 0.1524 | 0.7542 | 0.0118 | 0.1301 | 0.9282 |
| Est (estimates), SE (sta | andard erro | or), pso (po | ost symptoi | m onset) | | | | | | | | | | | | | | |

Table S2d. Generalised linear regression models of CD8 T cell proliferative responses in SARS-CoV-2 recovered patients

| | CD4 Spike IFN-γ | | | С | D4 Spike I | L-2 | C | D4 Spike T | NF | C | 04 M+N IF | Ν-γ | С | D4 M+N II | L-2 | CD4 M+N TNF | | |
|------------------------------|-----------------|--------------|-------------|----------|------------|---------|---------|------------|---------|---------|-----------|---------|---------|-----------|---------|-------------|--------|---------|
| Coefficient | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value |
| Age | 0.3170 | 0.2982 | 0.3128 | 0.2555 | 0.2459 | 0.3233 | 0.2092 | 0.3048 | 0.5081 | 0.2674 | 0.3133 | 0.4135 | 0.1944 | 0.2594 | 0.4708 | -0.3688 | 0.3110 | 0.2632 |
| Sex (male) | 0.3723 | 0.6867 | 0.5996 | 1.0306 | 0.5663 | 0.0988 | 0.3834 | 0.7020 | 0.5970 | 0.2759 | 0.7215 | 0.7102 | 0.5908 | 0.5973 | 0.3460 | -0.2361 | 0.7162 | 0.7485 |
| DM (yes) | -0.7169 | 0.5252 | 0.2022 | -0.4192 | 0.4331 | 0.3560 | -0.4518 | 0.5369 | 0.4198 | -0.7481 | 0.5518 | 0.2050 | -0.3923 | 0.4568 | 0.4106 | 0.0420 | 0.5478 | 0.9403 |
| Obesity (yes) | 0.1716 | 0.6298 | 0.7908 | 0.1389 | 0.5193 | 0.7945 | 0.8563 | 0.6438 | 0.2130 | 0.5275 | 0.6617 | 0.4438 | -0.0329 | 0.5478 | 0.9533 | -0.1901 | 0.6568 | 0.7782 |
| Disease Severity (severe) | 0.3686 | 0.5900 | 0.5462 | 0.1065 | 0.4865 | 0.8312 | -0.4126 | 0.6031 | 0.5094 | -0.1854 | 0.6199 | 0.7710 | 0.2750 | 0.5132 | 0.6037 | -0.1665 | 0.6154 | 0.7922 |
| Days pso | -0.2078 | 0.3253 | 0.5373 | -0.3230 | 0.2683 | 0.2562 | 0.0027 | 0.3325 | 0.9936 | -0.1130 | 0.3418 | 0.7478 | -0.5099 | 0.2830 | 0.1017 | -0.4725 | 0.3393 | 0.1939 |
| Est (estimates), SE (sta | andard erro | or), pso (po | ost symptoi | m onset) | | | | | | | | | | | | | | |

Table S2e. Generalised linear regression models of CD4 T cell cytokine responses in SARS-CoV-2 recovered patients

| | CD8 Spike IFN-γ C | | | | D8 Spike I | L-2 | C | D8 Spike T | NF | CI | 08 M+N IF | Ν-γ | CD8 M+N IL-2 | | | CD8 M+N TNF | | |
|------------------------------|-------------------|--------------|-------------|----------|------------|---------|---------|------------|---------|---------|-----------|---------|--------------|--------|---------|-------------|--------|---------|
| Coefficient | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value | Est | SE | p value |
| Age | -0.3468 | 0.3103 | 0.2899 | -0.5560 | 0.2141 | 0.0266 | -0.2412 | 0.3162 | 0.4633 | -0.0623 | 0.3305 | 0.8542 | -0.5717 | 0.2919 | 0.0786 | -0.2982 | 0.2994 | 0.3427 |
| Sex (male) | -0.4403 | 0.7146 | 0.5516 | 0.1160 | 0.4930 | 0.8187 | -0.6419 | 0.7282 | 0.3987 | -0.1148 | 0.7610 | 0.8831 | 0.0510 | 0.6722 | 0.9410 | 0.3871 | 0.6893 | 0.5868 |
| DM (yes) | -0.6703 | 0.5465 | 0.2481 | -0.2953 | 0.3771 | 0.4516 | 0.2779 | 0.5569 | 0.6286 | -0.0871 | 0.5820 | 0.8840 | -0.1144 | 0.5141 | 0.8283 | 0.0486 | 0.5272 | 0.9284 |
| Obesity (yes) | -0.0194 | 0.6553 | 0.9770 | 1.2171 | 0.4521 | 0.0226 | 0.6295 | 0.6678 | 0.3680 | 0.6008 | 0.6979 | 0.4095 | 0.3194 | 0.6164 | 0.6156 | 0.6140 | 0.6322 | 0.3543 |
| Disease Severity (severe) | 0.6468 | 0.6140 | 0.3169 | 0.6714 | 0.4236 | 0.1441 | 0.6328 | 0.6256 | 0.3356 | -0.7529 | 0.6538 | 0.2763 | 0.2345 | 0.5775 | 0.6933 | -0.3396 | 0.5923 | 0.5790 |
| Days pso | 0.0369 | 0.3385 | 0.9154 | 0.3537 | 0.2335 | 0.1608 | 0.2361 | 0.3449 | 0.5091 | -0.0864 | 0.3605 | 0.8155 | -0.2600 | 0.3184 | 0.4332 | 0.0121 | 0.3265 | 0.9711 |
| Est (estimates), SE (sta | andard erro | or), pso (po | ost symptoi | m onset) | | | | | | | | | | | | | | |

Table S2f. Generalised linear regression models of CD8 T cell cytokine responses in SARS-CoV-2 recovered patients

| Marker | Fluorochrome | Clone | Isotype | Species reactivity | Host Species | Manufacturer | Catalogue number | Dilution used |
|--------|--------------|---------------|----------|-----------------------|-----------------|------------------|---------------------|------------------|
| CD14 | APC-Fire750 | M5E2 | lgG2a, к | Human | Mouse | Biolegend, UK | 301854 | 200 |
| CD3 | PerCP | UCHT1 | lgG1, к | Human | Mouse | Biolegend, UK | 300428 | 100 |
| CD3 | FITC | UCHT1 | lgG1, к | Human | Mouse | Biolegend, UK | 300440 | 50 |
| CD4 | APC | RPA-T4 | lgG1, к | Human | Mouse | Biolegend, UK | 300514 | 200 |
| CD8 | PE-Cy7 | RPA-T8 | lgG1, к | Human | Mouse | Biolegend, UK | 301012 | 200 |
| CD8 | BV510 | RPA-T8 | lgG1, к | Human | Mouse | Biolegend, UK | 301048 | 600 |
| IFN-γ | PE | 4S.B3 | lgG1, к | Human | Mouse | Biolegend, UK | 502508 | 50 |
| IL-2 | PE-Cy7 | MQ1- 17H12 | lgG2a, к | Human | Rat | eBioscience, USA | 25-7029- 41 | 100 |
| TNF | FITC | MAb11 | lgG1, к | Human | Mouse | Biolegend, UK | 502906 | 40 |

Table S3. Antibodies used for intracellular cytokine staining and proliferation assay

Methods

Generalised linear models

Generalised linear models (GLMs) were performed to estimate the association of obesity (categorical) and DM (categorical) with antibody, B cell, and T cell immune responses (all continuous and log-transformed) while adjusted for age (continuous), sex (discrete), disease severity (categorical) and days post symptoms onset (continuous) in SARS-CoV-2 recovered patients. All continuous variables were standardised by z-score normalisation. Normality of the data was tested by Shapiro–Wilk test, histogram, and Q-Q diagnostic plots. Interactions and co-linearity between variables were explored.

Model < - glm (immune response \sim age + sex + diabetes status + obesity category + disease severity + days post symptoms onset, data = data)